STOCK TITAN
  1. Home
  2. News
  3. BCRX

BioCryst Pharmaceuticals Inc - BCRX STOCK NEWS

Welcome to our dedicated page for BioCryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on BioCryst Pharmaceuticals stock.

BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) is a global biotechnology company dedicated to improving the lives of individuals living with rare and serious diseases. Founded in 1986, BioCryst specializes in designing, optimizing, and developing novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. Headquartered in Research Triangle Park, North Carolina, with a discovery center in Birmingham, Alabama, the company harnesses its expertise in drug discovery, clinical development, regulatory affairs, and product commercialization.

BioCryst is known for its flagship product, ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor specifically designed to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients aged 12 years and older. The efficacy of ORLADEYO has been demonstrated through multiple clinical studies and real-world data, showing significant reductions in HAE attack rates across various patient profiles.

The company's robust pipeline includes several innovative programs such as BCX17725 for Netherton syndrome and avoralstat for diabetic macular edema (DME). BioCryst's research spans multiple scientific disciplines, including biology, computer modeling, and medicinal chemistry, targeting therapeutic areas like acute uncomplicated influenza, hereditary angioedema, filoviruses (Ebola and Marburg), and oncology.

In recent announcements, BioCryst reported strong financial performance with ORLADEYO net revenue experiencing substantial growth. The company also continues to expand globally, with recent approvals of ORLADEYO in major markets, including Brazil and Mexico. Partnerships with organizations such as Pint Pharma help BioCryst extend its reach and bring life-changing treatments to patients worldwide.

BioCryst remains committed to advancing its clinical programs, generating new compounds, and upholding a culture of engagement and accountability. The company's ongoing dedication to developing innovative therapeutics aims to address unmet medical needs and provide better health outcomes for patients suffering from rare and serious conditions.

For more information, please visit www.biocryst.com or follow them on LinkedIn.

News

BioCryst Launches ORLADEYO® (berotralstat) in Italy

Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. (BCRX) receives a positive recommendation from the Italian Medicines Agency for ORLADEYO® (berotralstat) for the prevention of recurrent attacks of hereditary angioedema (HAE) in Italy, expanding access to a groundbreaking therapy for eligible patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

BioCryst to Report Fourth Quarter 2023 Financial Results on February 26

Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. (BCRX) will report its fourth quarter 2023 financial results on February 26, 2024. The company will host a conference call to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
conferences earnings
-
News

BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) is set to present five abstracts at the 2024 American Academy of Allergy, Asthma & Immunology annual meeting, focusing on the real-world use of ORLADEYO for the prophylactic treatment of hereditary angioedema (HAE) in patients 12 years and older. The abstracts feature new analyses and will cover topics such as reduction of HAE attack rates, tolerability, adherence, and effectiveness of berotralstat in patients with HAE, with and without C1-inhibitor deficiency. The meeting will take place from February 23-26, 2024, at the Walter E. Washington Convention Center in Washington, D.C.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
conferences
News

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) recently granted nine newly-hired employees stock options to purchase an aggregate of 32,100 shares and restricted stock units (RSUs) covering an aggregate of 21,450 shares. The options and RSUs were granted as inducements material to each employee entering into employment with BioCryst. The options have an exercise price of $5.30 per share and vest in four equal annual installments beginning on the one-year anniversary of the grant date, subject to the new employee’s continued service with the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
none
-
News

BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability

Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced preliminary, unaudited ORLADEYO net revenue for the fourth quarter and full year 2023, with a 29% year-over-year increase to $325 million. The company expects net revenue to be between $380-$400 million in 2024, aiming for $1 billion in peak sales. Operating expenses are projected to remain flat at $365-$375 million in 2024, with an expected operating profit in 2024 and positive cash flow in 2H 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.62%
Tags
none
-
News

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) granted stock options and restricted stock units to eight newly-hired employees. The options and RSUs total 48,700 and 34,000 shares, respectively, with an exercise price of $5.99 per share. Vesting occurs in four equal annual installments, subject to continued service, with each option having a 10-year term.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.67%
Tags
none
News

BioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. (BCRX) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
conferences
-
News

BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)

Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announces publication of data from the open-label extension (OLE) of the APeX-2 trial of ORLADEYO for the prophylactic treatment of hereditary angioedema (HAE) in patients 12 years and older. Results show rapid and sustained reductions in HAE attacks and improved quality of life over 96 weeks of treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
none
-
News

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) granted 16 newly-hired employees stock options to purchase 74,500 shares and restricted stock units covering 51,050 shares. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and have an exercise price of $5.88 per share, vesting in four equal annual installments beginning on the one-year anniversary of the grant date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.11%
Tags
none
News

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina

Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) has received approval from ANMAT in Argentina for ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema attacks in adults and pediatric patients 12 years of age or older. The partnership with Pint Pharma GmbH aims to bring ORLADEYO to patients in Latin America, marking a significant step in improving the management of HAE attacks in the region.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
none

FAQ

What is the current stock price of BioCryst Pharmaceuticals (BCRX)?

The current stock price of BioCryst Pharmaceuticals (BCRX) is $7.23 as of January 15, 2025.

What is the market cap of BioCryst Pharmaceuticals (BCRX)?

The market cap of BioCryst Pharmaceuticals (BCRX) is approximately 1.5B.

What is BioCryst Pharmaceuticals' main product?

BioCryst Pharmaceuticals' main product is ORLADEYO® (berotralstat), an oral, once-daily plasma kallikrein inhibitor designed to prevent attacks of hereditary angioedema (HAE).

Where is BioCryst Pharmaceuticals headquartered?

BioCryst Pharmaceuticals is headquartered in Research Triangle Park, North Carolina, with a discovery center in Birmingham, Alabama.

What therapeutic areas does BioCryst Pharmaceuticals focus on?

BioCryst Pharmaceuticals focuses on therapeutic areas such as acute uncomplicated influenza, hereditary angioedema, filoviruses (Ebola and Marburg), and oncology.

What recent achievements has BioCryst Pharmaceuticals reported?

BioCryst Pharmaceuticals has reported strong financial performance with significant growth in ORLADEYO® net revenue and recent approvals of ORLADEYO in Brazil and Mexico.

How does ORLADEYO® work?

ORLADEYO® works by decreasing the activity of plasma kallikrein, thereby preventing hereditary angioedema (HAE) attacks.

What is the pipeline of BioCryst Pharmaceuticals?

The pipeline of BioCryst Pharmaceuticals includes programs like BCX17725 for Netherton syndrome and avoralstat for diabetic macular edema (DME).

Who are BioCryst Pharmaceuticals' partners?

BioCryst Pharmaceuticals partners with organizations such as Pint Pharma to extend their reach and bring treatments to patients worldwide.

What is the company's approach to drug development?

BioCryst Pharmaceuticals leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics targeting difficult-to-treat diseases.

What are some of the challenges BioCryst Pharmaceuticals addresses?

BioCryst Pharmaceuticals addresses challenges in rare and serious diseases by developing innovative therapeutics to meet unmet medical needs and improve health outcomes.

How can I stay updated on BioCryst Pharmaceuticals' latest news?

You can stay updated on BioCryst Pharmaceuticals' latest news by visiting their website at www.biocryst.com or following them on LinkedIn.
Stock BCRX logo
BioCryst Pharmaceuticals Inc

Nasdaq:BCRX

BCRX Rankings

#2203 Ranked by Market Cap
N/A Ranked by Dividends

BCRX Stock Data

1.50B
200.27M
1.46%
85.11%
8.35%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
DURHAM